More than 250 million people worldwide are chronically infected with the hepatitis B virus (HBV). In this Comment, members of the International Coalition to Eliminate HBV appraise the current policy environment and the need for appropriate cure research and preparedness to complement the WHO global elimination strategy, the HBV vaccine and the well-tolerated but poorly accessed therapy.
Access options
Subscribe to Journal
Get full journal access for 1 year
$213.00
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
Additional information
WHO/UNICEF birth-dose vaccination coverage estimates: http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragebcg.html
References
- 1.
Razavi-Shearer, D. et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383–403 (2018).
- 2.
World Health Organization. Global health sector strategy on viral hepatitis, 2016–2021. Towards ending viral hepatitis (WHO, 2016).
- 3.
Papatheodoridis, G. V. et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J. Hepatol. 62, 956–967 (2015).
- 4.
World Health Organization. Global hepatitis report 2017 (WHO, 2017).
- 5.
Fattovich, G., Bortolotti, F. & Donato, F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J. Hepatol. 48, 335–352 (2008).
- 6.
United Nations. Transforming our world: the 2030 agenda for sustainable development. (UN General Assembly, 2015).
- 7.
Stenberg, K. et al. Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Global Health 5, e875–e887 (2017).
- 8.
Revill, P. et al. Global strategies are required to cure and eliminate HBV infection. Nat. Rev. Gastroenterol. Hepatol. 13, 239–248 (2016).
- 9.
Nayagam, S. et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet. Infect. Dis. 16, 1399–1408 (2016).
- 10.
Sugarman, J. et al. Ethics and hepatitis B cure research. Gut 66, 389–392 (2017).
Acknowledgements
The authors thank J. Pericàs and H. Nde for their input into an earlier draft of this article.
Author information
Affiliations
Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
- Jeffrey V. Lazarus
Baruch S. Blumberg Institute, Doylestown, PA, USA
- Timothy Block
Global Virus Network, Baltimore, MD, USA
- Christian Bréchot
Hepatitis Virus Diversity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- Anna Kramvis
Forum for Collaborative Research, School of Public Health, University of California, Berkeley, CA, USA
- Veronica Miller
World Hepatitis Alliance, London, UK
- Michael Ninburg
International Coalition to Eliminate HBV (ICE-HBV), The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia
- Capucine Pénicaud
German Center for Infection Research (DZIF), Munich partner site, Munich, Germany
- Ulrike Protzer
Center for Disease Analysis Foundation, Lafayette, CO, USA
- Homie Razavi
WHO Collaborating Centre for Viral Hepatitis, Doherty Institute, Melbourne, Australia
- Laura A. Thomas
- & Benjamin C. Cowie
Burnet Institute, Melbourne, Australia
- Jack Wallace
Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia
- Benjamin C. Cowie
Authors
Search for Jeffrey V. Lazarus in:
Search for Timothy Block in:
Search for Christian Bréchot in:
Search for Anna Kramvis in:
Search for Veronica Miller in:
Search for Michael Ninburg in:
Search for Capucine Pénicaud in:
Search for Ulrike Protzer in:
Search for Homie Razavi in:
Search for Laura A. Thomas in:
Search for Jack Wallace in:
Search for Benjamin C. Cowie in:
Competing interests
The authors declare no competing interests.
Corresponding author
Correspondence to Jeffrey V. Lazarus.
Supplementary information
Rights and permissions
To obtain permission to re-use content from this article visit RightsLink.